Navigation Links
InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
Date:3/18/2009

involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 16, 2009 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related to the long, expensive and uncertain clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues or delays in anticipated timing of the regulatory approval process; (ii) risks related to failure to achieve the clinical trial results required to commercialize our product candidates; and (iii) risks related to timely patient enrollment and retention in clinical trials. The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web site at www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
2. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
3. InterMune Announces Issuance of U.S. Patent for ITMN-191
4. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
5. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
6. InterMune to Present at J.P. Morgan Healthcare Conference
7. InterMune to Present at Deutsche Bank Biotech Boston Confab
8. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
9. InterMune to Release Third Quarter 2008 Financial Results on November 6
10. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
11. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... OAKS, Calif. , July 25, 2014 ... Board of Directors today declared a $0.61 per share ... will be paid on Sept. 5, 2014, to all ... on Aug. 14, 2014.  About Amgen ... for patients suffering from serious illnesses by discovering, developing, ...
(Date:7/25/2014)... , July 25, 2014 ... the "Global Metabolomics Market 2014-2018" report ... http://photos.prnewswire.com/prnh/20130307/600769 Metabolomics or Metabonomics is ... Metabolomics has become a new experimental technique that ... the environmental sciences. Metabolites are small molecules that ...
(Date:7/25/2014)... July 25, 2014 The Conferee Networking ... Topics for Conferee Networking. These two-hour sessions provide a ... meet and resolve problems, discuss new techniques, or brainstorm ... to submit a topic for consideration is August 31, ... . The Conferee Networking committee will review the topics, ...
(Date:7/25/2014)... 2014 /PRNewswire-iReach/ -- Xybion Corporation, the leading provider ... operating in highly regulated industries, announced today that ... User Group Conference, Xybion International Exchange, on October ... at the Sheraton Society Hill Hotel.  ... This year,s conference theme is Compliance ...
Breaking Biology Technology:Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon 2Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3
... Jan. 24 Cardica, Inc.,(Nasdaq: CRDC ) ... fiscal 2008 second quarter and six months ended ... excellent commercial progress, with over 1,000,C-Port systems shipped ... an expanding,product line designed to enable minimally-invasive cardiac ...
... FRAZER, Pa. and MAISONS-ALFORT, France, Jan. 24 /PRNewswire-FirstCall/,-- ... that the European,Committee for Medicinal Products for Human ... a positive opinion regarding EFFENTORA(TM), the,company,s fentanyl buccal ... EFFENTORA European new drug application for the treatment ...
... DIEGO, Jan. 24 Biomatrica, the biostability company,that ... temperature, has introduced RNAstable(TM) for preserving RNA at ... shipping., Interest in RNA has skyrocketed over ... gene silencer and in gene expression studies. However, ...
Cached Biology Technology:Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 2Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 3Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 4Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 5Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 6Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 7Cephalon's EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 2Cephalon's EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 3Cephalon's EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 4Biomatrica's RNAstable(TM) Stabilizes RNA at Room Temperature 2Biomatrica's RNAstable(TM) Stabilizes RNA at Room Temperature 3
(Date:7/25/2014)... healthcare community and remain priority areas that ... the worldwide crisis of obesity and diabetes, ... in diabetes, epidemiology and public health describe ... of diverse intervention programs in this novel ... on "Global Health Perspectives in Prediabetes and ...
(Date:7/25/2014)... is a complex congenital central nervous system disease ... the neural tubes during the embryonic phase. Many ... fecal incontinence and neurocognitive retardation. Such problems decrease ... life. Researchers at Ankara Physical Medicine and Rehabilitation ... performance in children with SB, using the Pediatric ...
(Date:7/25/2014)... Institute for Medical Research have identified the functions ... crucial to triggering the mating process in mice. , ... mouse detect pheromones that indicate when a female is ... if the female mouse is ovulating and ready to ... mating. Stowers, researchers believe mice developed this system through ...
Breaking Biology News(10 mins):What constitutes an effective response to the global 'diabesity' tsunami? 2It takes two to court 2It takes two to court 3
... is uniquely a "dual" sense, in that the brain perceives ... nose rather than the mouth. In the August 18, 2005, ... of chocolate activated different brain regions according to whether the ... or through the nose. , In a joint research effort ...
... cancer melanoma, studying functional tissue rather than cell ... development, according to new research from a Howard ... School of Medicine. , Though multiple genetic alterations ... been able to establish a direct causal link ...
... a small molecule of RNA called microRNA ?a chemical cousin ... protein involved in the early development of heart muscle. , ... Nature, may aid scientists in their understanding of how a ... cell, as well as offer researchers a way to predict ...
Cached Biology News:Nose odors and mouth odors: The brain distinguishes 2Nose odors and mouth odors: The brain distinguishes 3Ibruprofen and other commonly used painkillers for treating inflammation may increase the risk of heart attack 2Ibruprofen and other commonly used painkillers for treating inflammation may increase the risk of heart attack 3MicroRNA tweaks protein that controls early heart development 2MicroRNA tweaks protein that controls early heart development 3
...
Mouse monoclonal [Ley 37D/G6] to LKB1 ( Abpromise for all tested applications). entrezGeneID: 6794 SwissProtID: Q15831...
... phase reagent for Virus ... & unique water insoluble ... detergents and chaotropes; Engineered ... non-envelop viruses while preserving ...
Integrins Sampler Kit 10g each...
Biology Products: